A Study for Patients With Osteoporosis

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the effect of injectable teriparatide to intranasal salmon calcitonin on lumbar spine bone mineral density, in the treatment of Chinese patients with established osteoporosis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Calcitonin; Calcitonin Gene-Related Peptide; Katacalcin; Salmon calcitonin; Teriparatide

Criteria

Inclusion Criteria:

• Clinical diagnosis of osteoporosis

• No other severe disabling conditions

• Should have at least 1 vertebral or non-vertebral prevalent fracture, and bone mineral density T-score should be less than -2.5

• Ambulatory

• Men (aged 40 to 85 years) or postmenopausal women (aged 55 to 85 years)

Exclusion Criteria:

• History of a disease that affects bone metabolism

• History of treatment with any drug that may significantly affect bone metabolism

• History or presence of liver disease

• History or presence of kidney disease

• History of excessive alcohol drinking or drug abuse